Iris T. Chan

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Antoni Ribas, René González, Anna C. Pavlick et al. · The Lancet Oncology · 2014 · 293 citations

Phase 1B, Medicine, Melanoma +7

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Jill M. Spoerke, Steven Gendreau, Kimberly Walter et al. · Nature Communications · 2016 · 292 citations · Full text

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease

Iris T. Chan, Jeffery L. Kutok, Ifor R. Williams et al. · Journal of Clinical Investigation · 2004 · 260 citations · Full text

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

John A. Flygare, Maureen H. Beresini, Nageshwar Budha et al. · Journal of Medicinal Chemistry · 2012 · 247 citations · Full text

Apoptosis, Cell Death, Clinical Candidate +20

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Geoffrey I. Shapiro, Patricia LoRusso, Eunice L. Kwak et al. · Investigational New Drugs · 2019 · 88 citations

Phase Ib Study, Mek Inhibitor Cobimetinib, Pi3k Inhibitor Pictilisib +6